ArticleLancet (London, England)2021
An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2.
Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Managing and mitigating future public health risks: Planetary boundaries, global catastrophic risk, and inclusive wealth.Risk analysis : an official publication of the Society for Risk Analysis · 2025Article
- Navigating the Nexus of Bioethics and Geopolitics: Implications for Global Health Security and Scientific Collaboration.Journal of bioethical inquiry · 2025Article
- Increased Susceptibility ofViruses · 2024Article
- Grand (meta) challenges in planetary health: environmental, social, and cognitive.Frontiers in public health · 2024Article
- An updated review of the scientific literature on the origin of SARS-CoV-2.Environmental research · 2022Review
- Article
- Comparing and contrasting two United Nations Environment Programme reports on COVID-19.Science in One Health · 2022Article
- The Lancet Commission on lessons for the future from the COVID-19 pandemic.Lancet (London, England) · 2022Review
- Type I interferons and SARS-CoV-2: from cells to organisms.Current opinion in immunology · 2022Review
- An active learning-based approach for screening scholarly articles about the origins of SARS-CoV-2.PloS one · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.